Neurogranin

Accounting for 60 to 70 % of cases, Alzheimer's disease is the most common cause of dementia in old age. The prevalence doubles for around every five years of age – 30 % of persons over 90 suffer from this disease. Alzheimer's disease is characterised as an increasing and irreversible deterioration of the cognitive capacities. The disease is divided into three consecutive phases: the preclinical stage, the MCI (mild cognitive impairment) stage and the dementia stage. neuropathological characteristics for Alzheimer's disease are protein agglomerations in the brain They lead to a progressive destruction of the nerve cells (neurodegeneration). Outside the nerve cells of patients with Alzheimer's disease, there are senile plaques which mainly consist of beta amyloid peptides (Aβ), amyloid pathology. They develop during the processing of the membrane-standing amyloid precursor protein (APP) by beta-secretase BACE1 and exist in different isoforms. Within the nerve cells there are neurofibrillary bundles of hyperphosphorylated tau proteins (tauopathy).

The quotient of CSF concentration of the two postsynaptic proteins neurogranin and BACE1 is a potential new biomarker for Alzheimer's disease. Some studies have shown that the neurogranin concentration in relation to the BACE1 concentration is increased in Alzheimer's patients and a high value is associated with faster progression of the cognitive impairment. Moreover, the quotient neurogranin/BACE1 can help to delimit Alzheimer's patients in an early disease stage from patients with depression and cognitive impairment

  • Highly specific ELISA for the determination of neurogranin (Trunc P75) in CSF 
  • Optimised protocol: Results obtained in 4:00 hours
  • Efficient processing: Standardised protocols of neurodegeneration ELISAs
  • Convenient automation solutions
ProductSample typeRegulatory statusOrder no.
Neurogranin ELISACSFRUO*EQ 6551-9601-L
BACE1 ELISACSFRUO*EQ 6541-9601-L

*For research use only